As a group, patients with normal tension glaucoma benefit from lowering of IOP. Variable
rate of deterioration, as well as lack of progression in a substantial number in 5 years …

Based on the body of evidence implicating ocular blood flow disturbances in the
pathogenesis of glaucoma, there is great interest in the investigation of the effects of …

Objective To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT),
including the effect of EMGT treatment. Setting/Participants Two hundred fifty-five open …

purpose. To develop a modified adenoassociated viral (AAV) vector capable of efficient
transfection of retinal ganglion cells (RGCs) and to test the hypothesis that use of this vector …

Purpose Diurnal variation in intraocular pressure (IOP) is well recognized, yet important
decisions in glaucoma management are frequently made after 1 or 2 IOP measurements …

PURPOSE: To study whether the benefit of lowering of intraocular pressure (IOP) varies
according to certain traits. DESIGN: Randomized clinical trial, secondary analysis …

Background The long-term efficacy and safety of primary trabeculectomy with mitomycin C
were retrospectively studied. Methods Sixty eyes of 60 patients with severe glaucoma, 25 …

purpose. To compare the performance characteristics of seven methods for analyzing
glaucomatous visual field progression, using a combination of real patient data and …

In most patients, chronic open‐angle glaucoma is a slowly progressive disease. Eyes with
very high intraocular pressure (IOP> 30 mmHg) represent an exception to this and should be …

Latanoprost (Xalatan®) is an ester analogue of prostaglandin F 2α that reduces intraocular
pressure (IOP) by increasing uveoscleral outflow. The IOP-lowering efficacy of latanoprost …